BCAB BioAtla: Earnings per share for the last 12 months

BioAtla Corp (BCAB) - corporate logo

This daily price chart for BioAtla, Inc. (BCAB) reflects an EPS of 53.40. Price action is complicated by the threat of clinical failures and a high cash burn rate, forcing the company to scale back certain projects. Meanwhile, BioAtla, Inc. (BCAB) develops selective antibodies to combat various tumors, while drug manufacturing is delegated to external partners in California.

BioAtla Corp (BCAB) Earnings per share for the last twelve months: for the period 02/11/2024 - 09/06/2026

BCAB (BioAtla Corp): analytical breakdowns and indicator data

- price and consensus price forecast:
Market Price BioAtla, Inc.|BCAB - Price Target Chart
- company stock capitalization data:
Market Capitalization BioAtla Inc|BCAB - Enterprise Value
- book capitalization indicators:
Accounting Value per Share BioAtla|BCAB - Company Book Value|Market-to-Book Ratio bioatla.com|BCAB - Aggregate Company Assets
- company total debt and liquidity indicators:
Debt to Equity BioAtla, Inc.|BCAB - Long-Term Debt to Equity|Current Liabilities to Capital BioAtla, Inc.|BCAB - Company Aggregate Debts|Debt to Net Assets BioAtla Inc|BCAB - Company Long-Term Liabilities|Short-Term Debt BioAtla|Intermediate Coverage Ratio bioatla.com
- earnings and market multiples details:
BCAB - Net Income|Future Net Profit BioAtla, Inc.|BCAB - P/E Multiple|Future Price to Earnings Multiple BioAtla, Inc.|BCAB - PEG Multiple|Company Value to EBITDA BioAtla Inc|BCAB - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year BioAtla|BCAB - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth bioatla.com|BCAB - Earnings per share growth in current year|Net earnings per share change forecast for next year BioAtla, Inc.
Fundamental company valuation:BCAB BioAtla
Flagship merchandise of BioAtla Inc

The dynamics of trailing twelve-month earnings per share assess the operational resilience of the business, smoothing out one-time financial spikes to identify the real profitability trend. For BioAtla, Inc. (BCAB), whose revenues depend on antibody clinical trial milestones and partner payments, the 12-month growth in earnings per share serves as an indicator of the efficiency of innovation capitalization and expense control.

Direct competitors

Net earnings per one share for the last twelve months incyte.com|HUTCHMED (HCM) - Earnings per share for the last twelve months|Earnings per share for the last 12 months NUVB|DAWN (Day One Bio) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months Monopar Corp (MNPR)|Earnings per share for the last twelve months Inhibrx Biosciences (INBX)|IMAB - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months Fennec Pharmaceuticals Inc. FENC|Heron - Earnings per share for the last twelve months|NVCT - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Coherus Biosciences|CRBP: Net earnings per share (EPS TTM)|Net earnings per share for the trailing year Cardiff Oncology CRDF|Net earnings per share for the last 12 months BYSI|Net earnings per one share for the last twelve months Lixte Biotechnology Holdings Inc. LIXT|Net earnings per share for the last 12 months CTXR (Citius Pharmaceuticals)|CLRB (Cellectar Corp) - Earnings per share for the trailing year|BioLineRx Ltd. - Net earnings per share for the last 12 months|Earnings per share for the last four quarters CANF (canfite.com)|Aprea - Net earnings per share (EPS TTM)|Earnings per share for the trailing year KZIA (Kazia Therapeutics)|SLXN: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months NuCana (NCNA)|Earnings per share for the last twelve months Chimerix, Inc.|CYCC: Earnings per share for the trailing year|Net earnings per share (EPS TTM) GTHX|Net earnings per share (EPS TTM) Kronos Bio Inc (KRON)|Earnings per share for the last twelve months Kintara KTRA|ONCT (Oncternal Corp) - Earnings per one share for the last 12 months|PRTG: Net earnings per share for the last 12 months